RMD on NYSE
Logo: Smoothape~commonswiki, CC0, via Wikimedia Commons4
Medical equipment company
Resmed Inc. is a medical equipment company based in San Diego, California, and founded in Australia.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 18, 2026.
Compare with Dexcom, Solventum or MiniMed Group, Inc., or pick any stock.
See how the biggest companies compare on our leaderboards
Resmed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19. Resmed also provides software to out-of-hospital care agencies to streamline transitions of care into and between these care settings for seniors and their care providers (i.e. home health, hospice, skilled nursing facilities, life plan communities, senior living centers, and private duty).3
From the company’s reports to the SEC. Every number links to the filing it came from.
Revenue by product, business segment and region, as the company reports it to the SEC.
Sleep and Breathing Health brought in 88% of the revenue ResMed broke down this way in fiscal 2026.
| Products and services | 2024 | 2025 | 2026 |
|---|---|---|---|
| Sleep and Breathing Health | $4.1B | $4.5B | $5.0B |
| Residential Care Software | $584.1M | $641.4M | $675.8M |
Sleep and Breathing Health brought in 88% of the revenue ResMed broke down this way in fiscal 2026.
| Business segments | 2024 | 2025 | 2026 |
|---|---|---|---|
| Sleep and Breathing Health | $4.1B | $4.5B | $5.0B |
| Residential Care Software | $584.1M | $641.4M | $675.8M |
United States brought in 63% of the revenue ResMed broke down this way in fiscal 2026.
| Regions | 2024 | 2025 | 2026 |
|---|---|---|---|
| United States | $3.0B | $3.3B | $3.6B |
| Outside the United States | $1.7B | $1.9B | $2.1B |
Out of $5.7B in revenue.5
Out of $1.8B of cash from operations.5
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Net revenue | $5.7B | $5.1B | $4.7B |
| Cost of sales (exclusive of amortization shown separately below) | $2.2B | $2.1B | $2.0B |
| Amortization of acquired intangible assets | $31.8M | $32.1M | $33.0M |
| Total cost of sales | $2.2B | $2.1B | $2.0B |
| Gross profit | $3.5B | $3.1B | $2.7B |
| Research and development | $378.3M | $331.3M | $307.5M |
| Selling, general, and administrative | $1.1B | $993.0M | $917.1M |
| Amortization of acquired intangible assets | $45.5M | $45.3M | $46.5M |
| Restructuring expenses (note 17) | $21.7M | $0 | $64.2M |
| Total operating expenses | $1.6B | $1.4B | $1.3B |
| Income from operations | $1.9B | $1.7B | $1.3B |
| Interest income (expense), net | $49.9M | $4.1M | -$45.7M |
| Gain (loss) attributable to equity method investments (note 6) | $7.0M | $3.6M | -$1.8M |
| Gain (loss) on equity investments (note 6) | -$15.0M | -$10.3M | -$4.0M |
| Other, net | -$9.2M | -$5.3M | -$3.5M |
| Total other income (loss), net | $32.7M | -$7.8M | -$55.1M |
| Income before income taxes | $1.9B | $1.7B | $1.3B |
| Income taxes (note 12) | $396.1M | $276.8M | $243.8M |
| Net income | $1.5B | $1.4B | $1.0B |
| Basic earnings per share (note 11) (in dollars per share) | $10.47 | $9.55 | $6.94 |
| Diluted earnings per share (note 11) (in dollars per share) | $10.43 | $9.51 | $6.92 |
| Dividend declared per share (in dollars per share) | $2.40 | $2.12 | $1.92 |
| Basic shares outstanding (000's) (in shares) | 145.5M shares | 146.7M shares | 147.0M shares |
| Diluted shares outstanding (000's) (in shares) | 146.1M shares | 147.3M shares | 147.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 1997-04-30 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $1.5B | $1.2B | |||
| Accounts receivable, net of allowances of $25,839 and $22,424 at June 30, 2026 and June 30, 2025, respectively | $1.0B | $939.5M | |||
| Inventories (note 4) | $945.8M | $927.7M | |||
| Prepaid expenses and other current assets (note 4) | $416.1M | $429.0M | |||
| Assets held for sale (note 18) | $457.4M | $0 | |||
| Total current assets | $4.3B | $3.5B | |||
| Property, plant and equipment, net (note 4) | $581.8M | $550.8M | |||
| Operating lease right-of-use assets (note 9) | $153.2M | $167.5M | |||
| Goodwill (note 5) | $2.9B | $3.0B | |||
| Other intangible assets, net (note 5) | $452.7M | $464.9M | |||
| Deferred income taxes (note 12) | $329.3M | $253.1M | |||
| Prepaid taxes and other non-current assets | $214.6M | $185.8M | |||
| Total non-current assets | $4.6B | $4.7B | |||
| Total assets | $9.0B | $8.2B | |||
| Accounts payable | $308.9M | $278.2M | |||
| Accrued expenses (note 7) | $494.9M | $402.3M | |||
| Operating lease liabilities, current (note 9) | $29.1M | $30.5M | |||
| Deferred revenue | $162.9M | $166.0M | |||
| Income taxes payable (note 12) | $98.1M | $132.3M | |||
| Short-term debt, net (note 8) | $259.9M | $9.9M | |||
| Liabilities held for sale (note 18) | $41.2M | $0 | |||
| Total current liabilities | $1.4B | $1.0B | |||
| Deferred revenue | $171.0M | $156.8M | |||
| Deferred income taxes (note 12) | $64.6M | $77.7M | |||
| Operating lease liabilities, non-current (note 9) | $137.4M | $153.0M | |||
| Other long-term liabilities | $213.0M | $141.5M | |||
| Long-term debt, net (note 8) | $399.4M | $658.4M | |||
| Total non-current liabilities | $985.4M | $1.2B | |||
| Total liabilities | $2.4B | $2.2B | |||
| Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued | $0 | $0 | |||
| Common stock, $0.004 par value, 350,000,000 shares authorized; 191,037,523 issued and 144,239,563 outstanding at June 30, 2026 and 190,311,097 issued and 146,385,350 outstanding at June 30, 2025 | $764.0K | $761.0K | |||
| Additional paid-in capital | $2.2B | $2.0B | |||
| Retained earnings | $7.3B | $6.1B | |||
| Treasury stock, at cost, 46,798,043 shares at June 30, 2026 and 43,925,747 shares at June 30, 2025 | -$2.8B | -$2.1B | |||
| Accumulated other comprehensive loss | -$82.5M | -$74.7M | |||
| Total stockholders equity | $6.6B | $6.0B | $4.9B | $4.1B | |
| Total liabilities and stockholders equity | $9.0B | $8.2B | |||
| Accounts receivable, allowance for credit loss, current | $25.8M | $22.4M | |||
| Preferred stock at par value (in dollars per share) | $0.01 | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | 2.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Common stock, shares authorized (in shares) | 350.0M shares | 350.0M shares | |||
| Common stock, shares issued (in shares) | 191.0M shares | 190.3M shares | |||
| Common stock, shares outstanding (in shares) | 144.2M shares | 146.4M shares | |||
| Treasury stock, shares (in shares) | 46.8M shares | 43.9M shares |
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 1997-04-30 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $1.5B | $1.2B | |||
| Accounts receivable, net of allowances of $25,839 and $22,424 at June 30, 2026 and June 30, 2025, respectively | $1.0B | $939.5M | |||
| Inventories (note 4) | $945.8M | $927.7M | |||
| Prepaid expenses and other current assets (note 4) | $416.1M | $429.0M | |||
| Assets held for sale (note 18) | $457.4M | $0 | |||
| Total current assets | $4.3B | $3.5B | |||
| Property, plant and equipment, net (note 4) | $581.8M | $550.8M | |||
| Operating lease right-of-use assets (note 9) | $153.2M | $167.5M | |||
| Goodwill (note 5) | $2.9B | $3.0B | |||
| Other intangible assets, net (note 5) | $452.7M | $464.9M | |||
| Deferred income taxes (note 12) | $329.3M | $253.1M | |||
| Prepaid taxes and other non-current assets | $214.6M | $185.8M | |||
| Total non-current assets | $4.6B | $4.7B | |||
| Total assets | $9.0B | $8.2B | |||
| Accounts payable | $308.9M | $278.2M | |||
| Accrued expenses (note 7) | $494.9M | $402.3M | |||
| Operating lease liabilities, current (note 9) | $29.1M | $30.5M | |||
| Deferred revenue | $162.9M | $166.0M | |||
| Income taxes payable (note 12) | $98.1M | $132.3M | |||
| Short-term debt, net (note 8) | $259.9M | $9.9M | |||
| Liabilities held for sale (note 18) | $41.2M | $0 | |||
| Total current liabilities | $1.4B | $1.0B | |||
| Deferred revenue | $171.0M | $156.8M | |||
| Deferred income taxes (note 12) | $64.6M | $77.7M | |||
| Operating lease liabilities, non-current (note 9) | $137.4M | $153.0M | |||
| Other long-term liabilities | $213.0M | $141.5M | |||
| Long-term debt, net (note 8) | $399.4M | $658.4M | |||
| Total non-current liabilities | $985.4M | $1.2B | |||
| Total liabilities | $2.4B | $2.2B | |||
| Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued | $0 | $0 | |||
| Common stock, $0.004 par value, 350,000,000 shares authorized; 191,037,523 issued and 144,239,563 outstanding at June 30, 2026 and 190,311,097 issued and 146,385,350 outstanding at June 30, 2025 | $764.0K | $761.0K | |||
| Additional paid-in capital | $2.2B | $2.0B | |||
| Retained earnings | $7.3B | $6.1B | |||
| Treasury stock, at cost, 46,798,043 shares at June 30, 2026 and 43,925,747 shares at June 30, 2025 | -$2.8B | -$2.1B | |||
| Accumulated other comprehensive loss | -$82.5M | -$74.7M | |||
| Total stockholders equity | $6.6B | $6.0B | $4.9B | $4.1B | |
| Total liabilities and stockholders equity | $9.0B | $8.2B | |||
| Accounts receivable, allowance for credit loss, current | $25.8M | $22.4M | |||
| Preferred stock at par value (in dollars per share) | $0.01 | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | 2.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Common stock, shares authorized (in shares) | 350.0M shares | 350.0M shares | |||
| Common stock, shares issued (in shares) | 191.0M shares | 190.3M shares | |||
| Common stock, shares outstanding (in shares) | 144.2M shares | 146.4M shares | |||
| Treasury stock, shares (in shares) | 46.8M shares | 43.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Net income | $1.5B | $1.4B | $1.0B |
| Depreciation and amortization | $201.3M | $198.5M | $176.9M |
| Amortization of right-of-use assets | $42.8M | $37.3M | $39.3M |
| Stock-based compensation costs (note 10) | $104.3M | $91.7M | $80.2M |
| (Gain) loss attributable to equity method investments, net of dividends received (note 6) | -$2.4M | -$3.6M | $1.8M |
| (Gain) loss on equity investments (note 6) | $15.0M | $10.3M | $4.0M |
| Gain on previously held equity investment (note 6) | -$4.4M | $0 | $0 |
| Restructuring expenses (note 17) | $0 | $0 | $33.2M |
| Accounts receivable | -$96.8M | -$76.7M | -$134.3M |
| Inventories | -$9.9M | -$80.2M | $172.2M |
| Prepaid expenses, net deferred income taxes and other current assets | -$140.3M | $82.6M | -$115.2M |
| Accounts payable, accrued expenses and other | $172.7M | $91.0M | $122.1M |
| Net cash provided by (used in) operating activities | $1.8B | $1.8B | $1.4B |
| Purchases of property, plant and equipment | -$156.3M | -$89.9M | -$99.5M |
| Patent registration costs | -$18.7M | -$10.8M | -$15.4M |
| Purchases of intangible assets | -$2.2M | $0 | $0 |
| Business acquisitions, net of cash acquired | -$350.7M | -$139.2M | -$133.5M |
| Purchases of investments (note 6) | -$28.5M | -$6.4M | -$12.8M |
| Proceeds from exits of investments (note 6) | $2.8M | $4.6M | $1.0M |
| Proceeds (payments) on maturity of foreign currency contracts | $8.5M | $41.6M | -$9.7M |
| Net cash provided by (used in) investing activities | -$545.2M | -$200.0M | -$269.8M |
| Proceeds from issuance of common stock, net | $74.5M | $74.4M | $53.1M |
| Taxes paid related to net share settlement of equity awards | -$21.8M | -$18.1M | -$8.8M |
| Purchases of treasury stock | -$700.0M | -$300.0M | -$150.0M |
| Payments of business combination contingent consideration | $0 | -$855.0K | -$1.3M |
| Acquisition of consolidated subsidiary | $0 | -$10.9M | $0 |
| Proceeds from borrowings, net of borrowing costs | $0 | $0 | $105.0M |
| Repayment of borrowings | -$10.0M | -$40.0M | -$835.0M |
| Dividends paid | -$349.7M | -$310.9M | -$282.3M |
| Net cash provided by (used in) financing activities | -$1.0B | -$606.3M | -$1.1B |
| Effect of exchange rate changes on cash | $6.2M | $25.8M | -$1.7M |
| Net increase (decrease) in cash and cash equivalents | $259.8M | $971.1M | $10.5M |
| Income taxes paid, net of refunds | $357.2M | $214.0M | $278.4M |
| Interest paid | $27.1M | $28.4M | $45.7M |
| Fair value of assets acquired, excluding cash | $151.2M | $43.5M | $46.0M |
| Liabilities assumed | -$11.8M | -$6.3M | -$7.7M |
| Goodwill on acquisition | $222.9M | $101.3M | $92.2M |
| Previously held equity investment | -$7.4M | $0 | $0 |
| Deferred payments | -$1.0M | $670.0K | -$143.0K |
| Fair value of contingent consideration | -$3.2M | $855.0K | $4.4M |
| Cash paid for acquisitions | $350.7M | $140.1M | $134.8M |
No quarter-by-quarter statement was filed.
Founded by Peter Farrell in 1989.1
Resmed was established in June 1989 by Peter Farrell in Australia. The company opened an office in San Diego in 1992, and made that its headquarters two years later when it incorporated in the US.
From Wikipedia’s article on ResMed, shared under CC BY-SA 4.0.7
Who has led ResMed, and when. Pick a name to see everywhere that person has worked.
From Wikidata.1
In January 2020, Resmed Inc. agreed to pay more than $37.5 million to resolve alleged kickbacks paid to durable medical equipment suppliers, sleep labs, and other healthcare providers in violation of the Anti-Kickback Statute.
From Wikipedia’s article on ResMed, shared under CC BY-SA 4.0.7
608 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 40 major events, 368 insider forms, 13 large holders, 167 other. The latest 20:
The 608 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 13 such filings since October 2021, the latest 10:
From Forms 4 and Schedules 13D and 13G filed with the SEC.
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 12,317,194 | $2.4B | 0.0% | +223,171 |
| Vanguard Capital Management LLC | 9,474,129 | $1.8B | 0.0% | +7,713 |
| Vanguard Portfolio Management LLC | 7,913,661 | $1.5B | 0.1% | +49,739 |
| State Street Corp | 6,680,735 | $1.3B | 0.0% | +37,567 |
| Geode Capital Management, LLC | 4,352,320 | $845.2M | 0.0% | −553 |
| Bank of New York Mellon Corp | 4,197,610 | $818.0M | 0.1% | −727,776 |
| First Trust Advisors LP | 2,278,696 | $444.1M | 0.3% | +740,871 |
| Invesco Ltd. | 2,063,578 | $402.1M | 0.0% | +106,964 |
| Morgan Stanley | 1,928,931 | $375.9M | 0.0% | −757,890 |
| Northern Trust Corp | 1,696,674 | $330.6M | 0.0% | −29,019 |
| Nordea Investment Management Ab | 1,388,008 | $269.6M | 0.2% | +354,627 |
| Deutsche Bank Ag\ | 1,322,313 | $257.7M | 0.1% | −100,552 |
| UBS Group AG | 1,289,300 | $251.3M | 0.0% | +562,489 |
| Swedbank AB | 1,274,897 | $248.5M | 0.2% | −75,337 |
| Charles Schwab Investment Management Inc | 1,222,473 | $238.2M | 0.0% | +87,174 |
| Goldman Sachs Group Inc | 1,160,426 | $226.1M | 0.0% | +156,221 |
| Arrowstreet Capital, Limited Partnership | 1,129,739 | $220.2M | 0.1% | +679,489 |
| Dimensional Fund Advisors LP | 1,123,577 | $219.0M | 0.0% | +119,359 |
| Legal & General Group Plc | 942,614 | $183.7M | 0.0% | −47,747 |
| Aqr Capital Management LLC | 910,623 | $177.1M | 0.1% | +560,783 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 858,134 | $167.2M | 0.0% | +9,064 |
| Jpmorgan Chase & Co | 833,536 | $165.4M | 0.0% | +128,389 |
| Vanguard Fiduciary Trust Co | 814,716 | $158.8M | 0.0% | −10,360 |
| Bank Of America Corp /de/ | 775,424 | $151.1M | 0.0% | −153,006 |
| Citigroup Inc | 774,425 | $150.9M | 0.1% | +384,343 |
13F reports cover disclosed long positions in U.S. stocks only.
16 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Mar 27, 2026 | Alan ArmstrongRepublican, Senate | Buy | $1,001 - $15,000 | −11.8% | Report |
| Jun 4, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +32.6% | Report |
| Jun 4, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +32.6% | Report |
| Jun 4, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +32.6% | Report |
| Jun 4, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +32.6% | Report |
| Apr 28, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +36.7% | Report |
| Jan 13, 2025 | Robert P. Bresnahan, Jr.Republican, House | Sale | $1,001 - $15,000 | +27.6% | Report |
| May 3, 2024 | Tommy TubervilleRepublican, Senate | Sale | $1,001 - $15,000 | +39.3% | Report |
| Oct 17, 2023 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −6.2% | Report |
| Aug 29, 2023 | Thomas R Carper, Senate | Buy | $1,001 - $15,000 | −24.1% | Report |
| Jan 11, 2023 | Thomas R Carper, Senate | Sale | $1,001 - $15,000 | +82.2% | Report |
| Oct 5, 2022 | Tommy TubervilleRepublican, Senate | Sale | $1,001 - $15,000 | +100.2% | Report |
| Mar 30, 2022 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −71.0% | Report |
| Oct 26, 2021 | Tommy TubervilleRepublican, Senate | Sale | $1,001 - $15,000 | +78.8% | Report |
| Jul 9, 2020 | Thomas R Carper, Senate | Partial sale | $1,001 - $15,000 | +120.4% | Report |
| Apr 2, 2020 | Thomas R Carper, Senate | Partial sale | $1,001 - $15,000 | +145.1% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
The numbers on this page point here. Each one links to the record it came from.
